Sirolimus for children with juvenile nasal blood tumors
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests whether sirolimus can shrink or control juvenile nasopharyngeal angiofibroma in children and teens, and checks its safety. It may help families who cannot rely only on surgery, especially for larger or hard-to-treat tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of juvenile nasopharyngeal angiofibroma (JNA)
- You are a boy aged 7 to 18 years
- Your liver and kidney blood tests are in a safe range
- Your tumor size on an MRI is above a certain amount (tumor volume over 35 ml), or you fit the study’s follow-up groups
- You have not taken sirolimus (or similar mTOR medicines) before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether sirolimus (Rapamune®) can reduce problems from severe arteriovenous malformations (tangled blood vessel connections). It may help shrink the abnormal vessels or improve symptoms, by testing the medicine in people with certain AVM types.
This trial tests if sirolimus can help children with a certain type of eye socket malformation. It aims to find a better treatment for children aged 1 to 18.
This trial studies whether taking sirolimus once a week can improve blood vessel, lymph vessel, or mixed (venolymphatic) malformations. It may help reduce symptoms and lesion size, while also monitoring safety in children and adults.
This Phase 2 study tests whether sirolimus combined with low-dose (“metronomic”) chemotherapy can help children and young adults with certain high-risk solid tumors stay in remission or reduce recurrence risk. It is designed for people whose cancer has responded well to initial treatment, with only minimal or no visible disease on scans.
This trial tests different doses of sirolimus (a medication that slows cell growth) to find the best dose for treating cystic lymphatic malformations in children. It may help shrink the abnormal fluid-filled growths and improve symptoms.
This Phase 3 study tests whether sirolimus helps control complex vascular anomalies that have not responded to standard treatments. It also checks safety by monitoring blood tests, organ function, and overall health during treatment.
Hear when a new Juvenile Nasopharyngeal Angiofibroma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.